The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD
Open accessAbstract
BACKGROUND: Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease (COPD). We prospectively studied the efficacy of simvastatin in preventing exacerbations in a large, multicenter, randomized trial. METHODS: We designed the Prospective Randomized Placebo-Controlled Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) as a randomized, controlled trial of simvastatin (at a daily dose of 40 mg) versus placebo, with annual exacerbation rates as the primary outcome. Patients were eligible if they were 40 to 80 years of age, had COPD (defined by a forced expiratory volume in 1 second [FEV1] of less than 80% and a ratio of FEV1 to forced vital capacity of less than 70%), and had a smoking history of 10 or more pack-years, were receiving supplemental oxygen or treatment with glucocorticoids or antibiotic agents, or had had an emergency department visit or hospitalization for COPD within the past year. Patients with diabetes or cardiovascular disease and those who were taking statins or who required statins on the basis of Adult Treatment Panel III criteria were excluded. Participants were treated from 12 to 36 months at 45 centers. RESULTS: A total of 885 participants with COPD were enrolled for approximately 641 days; 44% of the patients were women. The patients had a mean (±SD) age of 62.2±8.4 years, an FEV1 that was 41.6±17.7% of the predicted value, and a smoking history of 50.6±27.4 pack-years. At the time of study closeout, the low-density lipoprotein cholesterol levels were lower in the simvastatin-treated patients than in those who received placebo. The mean number of exacerbations per person-year was similar in the simvastatin and placebo groups: 1.36±1.61 exacerbations and 1.39±1.73 exacerbations, respectively (P=0.54). The median number of days to the first exacerbation was also similar: 223 days (95% confidence interval [CI], 195 to 275) and 231 days (95% CI, 193 to 303), respectively (P=0.34). The number of nonfatal serious adverse events per person-year was similar, as well: 0.63 events with simvastatin and 0.62 events with placebo. There were 30 deaths in the placebo group and 28 in the simvastatin group (P=0.89). CONCLUSIONS: Simvastatin at a daily dose of 40 mg did not affect exacerbation rates or the time to a first exacerbation in patients with COPD who were at high risk for exacerbations. (Funded by the National Heart, Lung, and Blood Institute and the Canadian Institutes of Health Research; STATCOPE ClinicalTrials.gov number, NCT01061671.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Self-citationMiller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Self-citationDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Spirometric Reference Values from a Sample of the General U.S. Population
HANKINSON, J. L., ODENCRANTZ, J. R., & FEDAN, K. B. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9712108 · Cited by 4,206
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D. A., Agusti, A., MacNee, W., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909883 · Cited by 2,981
Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
SEEMUNGAL, T. A. R., DONALDSON, G. C., PAUL, E. A., BESTALL, J. C., JEFFRIES, D. J., & WEDZICHA, J. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709032 · Cited by 2,312
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Soler-Cataluna, J. J. (2005) · Thorax · doi:10.1136/thx.2005.040527 · Cited by 1,931
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., & Decramer, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805800 · Cited by 1,604
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
Self-citationCalverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., & Maden, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12459-2 · Cited by 1,221
Jialal, I., Stein, D., Balis, D., Grundy, S. M., Adams-Huet, B., & Devaraj, S. (2001) · Circulation · doi:10.1161/01.cir.103.15.1933 · Cited by 730
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
MAAS Investigators (1994) · The Lancet · doi:10.1016/s0140-6736(94)92082-6 · Cited by 647
HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages
Bellosta, S., Via, D., Canavesi, M., Pfister, P., Fumagalli, R., Paoletti, R., & Bernini, F. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.11.1671 · Cited by 512
Collins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12475-0 · Cited by 492
Miniño, A., Murphy, S. L., Xu, J., & Kochanek, K. D. (2011) · PubMed · Cited by 473
Kinlay, S., Schwartz, G. G., Olsson, A. G., Rifai, N., Leslie, S. J., Sasiela, W. J., Szarek, M., Libby, P., & Ganz, P. (2003) · Circulation · doi:10.1161/01.cir.0000091404.09558.af · Cited by 405
Mancini, G. B. J., Etminan, M., Zhang, B., Levesque, L. E., FitzGerald, J. M., & Brophy, J. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.039 · Cited by 402
Influenza and COPD Mortality Protection as Pleiotropic, Dose-Dependent Effects of Statins
Frost, F. J., Petersen, H., Tollestrup, K., & Skipper, B. (2007) · Chest · doi:10.1378/chest.06-1997 · Cited by 302
Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect
Inoue, I., Goto, S.-I., Mizotani, K., Awata, T., Mastunaga, T., Kawai, S.-I., Nakajima, T., Hokari, S., Komoda, T., & Katayama, S. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00680-9 · Cited by 298
Design and analysis of group sequential tests based on the type I error spending rate function
KIM, K., & DEMETS, D. L. (1987) · Biometrika · doi:10.1093/biomet/74.1.149 · Cited by 295
Statin use is associated with reduced mortality in COPD
Søyseth, V., Brekke, P. H., Smith, P., & Omland, T. (2007) · European Respiratory Journal · doi:10.1183/09031936.00106406 · Cited by 267
The Most Expensive Medical Conditions In America
Druss, B. G., Marcus, S. C., Olfson, M., & Pincus, H. A. (2002) · Health Affairs · doi:10.1377/hlthaff.21.4.105 · Cited by 235
A Multicenter Randomized Trial of Atorvastatin Therapy in Intensive Care Patients with Severe Sepsis
Kruger, P., Bailey, M., Bellomo, R., Cooper, D. J., Harward, M., Higgins, A., Howe, B., Jones, D., Joyce, C., Kostner, K., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201209-1718oc · Cited by 220
Balk, E. M., Lau, J., Goudas, L. C., Jordan, H. S., Kupelnick, B., Kim, L. U., & Karas, R. H. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00011 · Cited by 185
Statin Use Is Associated with Improved Function and Survival of Lung Allografts
Johnson, B. A., Iacono, A. T., Zeevi, A., McCurry, K. R., & Duncan, S. R. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200205-410oc · Cited by 185
Statin Use Reduces Decline in Lung Function: VA Normative Aging Study
Alexeeff, S. E., Litonjua, A. A., Sparrow, D., Vokonas, P. S., & Schwartz, J. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-656oc · Cited by 183
American translation, modification, and validation of the St. George's Respiratory Questionnaire
Barr, J. T., Schumacher, G. E., Freeman, S., LeMoine, M., Bakst, A. W., & Jones, P. W. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80089-2 · Cited by 180
Potential therapeutic role for statins in respiratory disease
Hothersall, E. (2006) · Thorax · doi:10.1136/thx.2005.057976 · Cited by 178
Impact of statins and ACE inhibitors on mortality after COPD exacerbations
Mortensen, E. M., Copeland, L. A., Pugh, M. J. V., Restrepo, M. I., de Molina, R. M., Nakashima, B., & Anzueto, A. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-45 · Cited by 170
Blamoun, A. I., Batty, G. N., DeBari, V. A., Rashid, A., Sheikh, M., & Khan, M. A. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01731.x · Cited by 141
The Use of Statins and Lung Function in Current and Former Smokers
Keddissi, J. I., Younis, W. G., Chbeir, E. A., Daher, N. N., Dernaika, T. A., & Kinasewitz, G. T. (2007) · CHEST Journal · doi:10.1378/chest.07-0298 · Cited by 134
Wyrwich, K. W., Fihn, S. D., Tierney, W. M., Kroenke, K., Babu, A. N., & Wolinsky, F. D. (2003) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2003.20203.x · Cited by 133
Statins, systemic inflammation and risk of death in COPD: The Rotterdam study
Lahousse, L., Loth, D. W., Joos, G., Albert Hofman, D., Leufkens, H. G. M., Brusselle, G., & Stricker, B. H. C. (2012) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2012.10.008 · Cited by 131
Direct costs of chronic obstructive pulmonary disease among managed care patients
Dalal, A. A. (2010) · International Journal of COPD · doi:10.2147/copd.s13771 · Cited by 127
Lee, T., Chen, C., Shen, H.-N., & Chang, N. (2008) · Clinical Science · doi:10.1042/cs20080241 · Cited by 104
with chronic obstructive pulmonary disease Severe acute exacerbations and mortality in patients
Ochando, R., Soler‐Cataluña, J. J., Martínez‐García, M. Á., Sánchez, P. R., Salcedo, E., & Navarro, M. (2006) · Cited by 103
Ishida, W., Kajiwara, T., Ishii, M., Fujiwara, F., Taneichi, H., Takebe, N., Takahashi, K., Kaneko, Y., Segawa, I., Inoue, H., et al. (2007) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.212.265 · Cited by 55
Calverley, P. M., PAUWELS, R. A., & Vestbo, J. (2003) · Ghent University Academic Bibliography (Ghent University) · Cited by 18
Cited by
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
Self-citationInterpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Self-citationChen, W., Thomas, J., Sadatsafavi, M., & FitzGerald, J. M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00241-6 · Cited by 718
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Respirology · doi:10.1111/resp.13012 · Cited by 681
Self-citation
Metadata
- Authors
- Criner, G. J., Connett, J. E., Aaron, S. D., Albert, R. K., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Curtis, J. L., Dransfield, M. T., Han, M. K., Make, B., Marchetti, N., Martinez, F. J., Niewoehner, D. E., Scanlon, P. D., Sciurba, F. C., Scharf, S. M., Sin, D. D., Voelker, H., Washko, G. R., Woodruff, P. G., & Lazarus, S. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-06-05
- Volume
- 370
- Issue
- 23
- Pages
- 2201-2210
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2100858113
- Cited by
- 347
- References
- 45
- FWCI
- 36.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.